Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT versus EDROPHONIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT versus EDROPHONIUM CHLORIDE.
ARICEPT vs EDROPHONIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft of the central nervous system.
Inhibits acetylcholinesterase, prolonging acetylcholine action at neuromuscular junction and autonomic ganglia.
Initial: 5 mg orally once daily for 4-6 weeks; may increase to 10 mg once daily. Maximum: 10 mg per day. Route: oral. Frequency: once daily.
10 mg IV bolus, may repeat up to total 10 mg. For myasthenia gravis diagnosis: 2 mg IV test dose, then 8 mg IV if no reaction after 45 seconds.
None Documented
None Documented
70 hours (terminal elimination half-life; steady-state reached in 15-21 days; once-daily dosing appropriate)
Terminal elimination half-life is 1.5-2 hours; in anephric patients, half-life may be prolonged up to 6-8 hours, requiring dose adjustment.
Renal (57% unchanged drug, 17% as metabolites), fecal (30%), biliary (minimal)
Primarily renal excretion as unchanged drug (approximately 70-80% within 4 hours); minor biliary/fecal elimination accounts for <10%.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor